Anatoliy I. Martynov

Anatoliy I. Martynov

Auto-generated profile, based on publicly available information

Anatoliy I. Martynov

Russian University of Medicine

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
LLL. B. Lazebnik
L. B. Lazebnik
EGE. V. Golovanova
E. V. Golovanova
STS. V. Turkina
S. V. Turkina
KRK. L. Raikhelson
K. L. Raikhelson
SOS. V. Okovityy
S. V. Okovityy
ЮУЮ. П. Успенский
Ю. П. Успенский
Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия

5 December 2024 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
ATA. S. Trukhmanov
A. S. Trukhmanov
IMIgor V. Maev
Igor V. Maev
ODOxana M. Drapkina
Oxana M. Drapkina
Maria LivzanMaria Livzan
Maria Livzan
ЮУЮ. П. Успенский
Ю. П. Успенский
Aim. These recommendations are developed for practitioners in order to familiarize them with modern diagnostic methods, management features and pharmacotherapy of patients with gastroesophageal reflux disease (GERD).General provisions. GERD is the most common reason for patients to visit clinics. There are esophageal and extraesophageal manifestations of GERD. Patients' complaints of heartburn and regurgitation remain the most sensitive and specific clinical manifestations of GERD. The diagnosis of GERD is established on the basis of anamnestic data, instrumental examination (detection of reflux esophagitis during upper gastrointestinal endoscopy, detection of pathological gastroesophageal reflux with 24-hour pH-metry or/and 24-hour pH-impedance monitoring). Patients with suspected GERD and the absence of erosive and ulcerative changes in the mucous membrane of the esophagus or the presence of erosive esophagitis of Grade A according to Los Angeles Classification of Gastroesophageal Reflux Disease are recommended to conduct 24-hour pH-metry on PPI off to exclude or confirm the diagnosis of GERD. Patients with extraesophageal manifestations of GERD without classic symptoms (heartburn, regurgitation) are recommended to undergo 24-hour pH-impedance monitoring with discontinuation of proton pump inhibitor therapy. When deciding on surgical treatment, all patients need to perform high-resolution esophageal manometry and 24-hour pH-impedance monitoring. Complications of GERD include bleeding, strictures, Barrett’s esophagus and esophageal adenocarcinoma. The main groups of medications used in the treatment of GERD are proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs), alginates, antacids, and prokinetics. PPIs are the drugs of choice in the treatment of both symptoms of gastroesophageal reflux disease and existing erosive esophagitis. Combination therapy Rebamipide with PPIs increases the effectiveness of relief of GERD symptoms, as well as reduces the frequency of relapses.Conclusion. These clinical recommendations will improve the quality of medical care for patients with GERD.

24 February 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
VMV. I. Mazurov
V. I. Mazurov
AMA. I. Martynov
A. I. Martynov
ENE. L. Nasonov
E. L. Nasonov
SSS. A. Saiganov
S. A. Saiganov
ЮХЮ. Ш. Халимов
Ю. Ш. Халимов
Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике

8 May 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
VMV. I. Mazurov
V. I. Mazurov
AMA. I. Martynov
A. I. Martynov
IGI. Z. Gaidukova
I. Z. Gaidukova
Dmitry V. DuplyakovDmitry V. Duplyakov
Dmitry V. Duplyakov
ACA. I. Chesnikova
A. I. Chesnikova
Мочевая кислота (МК) — это конечный продукт пуринового обмена, являющийся основной составляющей клеточных запасов энергии, таких как аденозинтрифосфат (АТФ), а также компонентом дезоксирибонуклеиновой (ДНК) и рибонуклеиновой (РНК) кислот. На сегодняшний день в Российской Федерации нормальным показателем МК в сыворотке крови считается <360 мкмоль/л (6 мг/дл) для женщин и <420 мкмоль/л (7 мг/дл) для мужчин [1], в то время как Американская коллегия ревматологов рекомендует считать нормой уровень <360 мкмоль/л (6 мг/дл) [2,3], а Британское общество ревматологов - 40 кг/м2 , по сравнению с пациентами с ИМТ <25 кг/м2[1].В крупных эпидемиологических исследованиях было показано, что ГУ представляет собой модифицируемый фактор риска развития и прогрессирования основных хронических неинфекционных заболеваний, таких как артериальная гипертензия (в том числе преэклампсия) [5,6], атеросклеротические сердечно-сосудистые заболевания (ССЗ) [7], хроническая сердечная недостаточность [8], сахарный диабет 2 типа (СД 2 типа), хроническая болезнь почек (ХБП), метаболический синдром [9], синдром обструктивного апноэ во сне [10]. Данные многочисленных эпидемиологических и проспективных исследований позволяют утверждать, что бессимптомная ГУ также выступает мощным, независимым и модифицируемым сердечно-сосудистым фактором риска. В связи с этим возникла необходимость разработать алгоритм инициации и интенсификации уратснижающей терапии у пациентов в зависимости от сердечно-сосудистого риска.С этой целью 02 декабря 2022 г. под председательством академика РАН О.М. Драпкиной под эгидой Российского общества профилактики неинфекционных заболеваний состоялся Совет экспертов «В фокусе гиперурикемия». Группа экспертов была представлена ведущими специалистами в области терапии, кардиологии, общей врачебной практики, ревматологии, клинической фармакологии. В результате объединения усилий была подготовлена резолюция, отражающая междисциплинарное мнение экспертов по различным аспектам проблемы гиперурикемии, и сформулированы предложения.

17 December 2022 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
ALAleksandr M Lila
Aleksandr M Lila
VMV. I. Mazurov
V. I. Mazurov
AMA. I. Martynov
A. I. Martynov
NZNikolay Zagorodniy
Nikolay Zagorodniy
LAL. I. Alekseeva
L. I. Alekseeva
ETElena Taskina
Elena Taskina
Osteoarthritis (OA) is the most common joint disease due to the increasing life expectancy of the world's population. Every 2nd patient over the age of 50 suffers from knee or hip OA, and this is directly related to the increased burden on healthcare. Accumulated data on the comorbid profile of patients with OA dictate the need to identify disease phenotypes in order to provide personalized care. Individual clinical manifestations of OA also require a differential approach: the pain treatment requires consideration of the patient's psycho-emotional profile and the possibility of involving nociceptive pathways in the process. However, due to the ambiguity of existing clinical guidelines, most experts note a number of difficulties in prescribing treatment for patients with OA.The resolution presents an agreed opinion of experts on the algorithms for managing patients with OA, starting from the primary level, with the gradual involvement of related specialists. Some issues of a personalized approach are considered depending on the presence of comorbid pathology and the severity of individual symptoms of the disease. The prospects of the combined use of pharmacological and non-drug methods of treatment are noted; emphasis was placed on the importance of rehabilitation measures at the first level of medical care, provided to patients with OA, long before the development of structural changes.The proposed algorithms for managing patients can be considered as the basis for future recommendations for managing patients with this pathology.

8 September 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
GAG. P. Arutyunov
G. P. Arutyunov
SBSergey Boytsov
Sergey Boytsov
MVMikhail Voevoda
Mikhail Voevoda
ODOxana M. Drapkina
Oxana M. Drapkina
VKV. V. Kukharchuk
V. V. Kukharchuk
ЮХЮ. Ш. Халимов
Ю. Ш. Халимов
In opinion the Expert council provides management tactics for patients with hypertriglyceridemia (HTG). It is demonstrated that HTG is a common condition in overweight patients and is an important component of residual risk. HTG creates additional conditions for the progression of atherosclerosis, so the level of triglycerides (TG) is recommended to be measured in patients with a high, very high and extremely high risk level. An indication for the appointment of drugs that reduce the concentration of TG is its level of more than 2,3 mmol/L. Statins are the agents of choice to reduce the risk of cardiovascular disease in high-risk patients with hypercholesterolemia and HTG. Fenofibrate is used to correct HTG, and in case of intolerance to it or when the target level of TG is not reached, omega-3 ethers of polyunsaturated fatty acids in a dose of 2-4 g/day are recommended. In patients with HTG with a TG level >5,6 mmol/L, fenofibrate is the agent of choice.